Featured Research

from universities, journals, and other organizations

Treatment Advances For Lymphoma Have Reduced Deaths By 70%

Date:
October 21, 2005
Source:
University of Rochester Medical Center
Summary:
New treatment advances for patients with follicular lymphoma, previously considered an incurable cancer, have reduced deaths in the first four years by 70 percent. When scientists compared outcomes for 960 patients treated with three different treatment regimens, they found that patients treated with a combination of the standard therapy plus new monoclonal antibodies had the best four-year survival rate.

New treatment advances for patients with follicular lymphoma, previously considered an incurable cancer, have reduced deaths in the first four years by 70 percent. A newly published study recommends that doctors carefully choose their patients' initial therapies because there are significant differences in overall survival rates, according to researchers at the University of Rochester Medical Center's James P. Wilmot Cancer Center.

Scientists compared outcomes for 960 patients treated with three different regimens; survival rates vary from 91 percent for the newest treatments, which include monoclonal antibodies, to 69 percent for standard therapy.

"This is real evidence that the clinical advances we've made over the last 30 years are prolonging lives," said Richard I. Fisher, M.D., director of the Wilmot Cancer Center and lead author on a paper published online by the Journal of Clinical Oncology. "Some of the new therapies that include monoclonal antibodies have revolutionized treatment of this disease."

Follicular lymphoma, a slow-growing cancer of the lymphatic system, affects about 30,000 older adults each year in the U.S. Median survival has been seven to 10 years, but until this study, there was no evidence of any recent improvements.

Fisher and colleagues from the Southwest Oncology Group, Fred Hutchinson Cancer Research Center in Seattle and University of Arizona Cancer Center assessed three common therapies that have been used over the last two decades.

In the head-to-head comparison, they found that a combination of the standard therapy (a four-drug combination called CHOP, which stands for cyclophosphamide, doxorubicin, vincristine and prednisone) plus new monoclonal antibodies (rituximab or iodine-131 tositumomab) offers the best survival rate during the first four years. The team studied 179 patients who were treated with this regimen during the late 1990s, and the survival rate was 91 percent.

In the second arm of the study, the 425 patients treated during the 1980s with ProMACE-MOPP, an eight-drug, combo-chemotherapy regimen, had a 79-percent survival rate at the four-year point.

The third group of 356 patients received CHOP plus immunostimulant therapies during the 1970s; their four-year survival rate was 69 percent.

"This data gives doctors and patients real evidence that initial treatment decisions have significant impact on the length of survival," Fisher said.

Fisher has studied CHOP therapy and other combinations with the Southwest Oncology Group, one of the largest research cooperative groups, for the last three decades. He has led studies that demonstrated its effectiveness as a treatment for aggressive lymphomas.

The Wilmot Cancer Center has established one of the Northeast's largest hematologic malignancies teams, specializing in the multidisciplinary treatment of lymphomas and leukemias. Wilmot hematologists are currently comparing the two most effective therapies: CHOP plus rituximab and CHOP plus iodine-131 tositumomab.


Story Source:

The above story is based on materials provided by University of Rochester Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

University of Rochester Medical Center. "Treatment Advances For Lymphoma Have Reduced Deaths By 70%." ScienceDaily. ScienceDaily, 21 October 2005. <www.sciencedaily.com/releases/2005/10/051021021717.htm>.
University of Rochester Medical Center. (2005, October 21). Treatment Advances For Lymphoma Have Reduced Deaths By 70%. ScienceDaily. Retrieved September 16, 2014 from www.sciencedaily.com/releases/2005/10/051021021717.htm
University of Rochester Medical Center. "Treatment Advances For Lymphoma Have Reduced Deaths By 70%." ScienceDaily. www.sciencedaily.com/releases/2005/10/051021021717.htm (accessed September 16, 2014).

Share This



More Health & Medicine News

Tuesday, September 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

EU Ministers and Experts Meet to Discuss Ebola Reponse

EU Ministers and Experts Meet to Discuss Ebola Reponse

AFP (Sep. 15, 2014) The European Commission met on Monday to coordinate aid that the EU can offer to African countries affected by the Ebola outbreak. Duration: 00:58 Video provided by AFP
Powered by NewsLook.com
Despite The Risks, Antibiotics Still Overprescribed For Kids

Despite The Risks, Antibiotics Still Overprescribed For Kids

Newsy (Sep. 15, 2014) A new study finds children are prescribed antibiotics twice as often as is necessary. Video provided by Newsy
Powered by NewsLook.com
FDA Eyes Skin Shocks Used at Mass. School

FDA Eyes Skin Shocks Used at Mass. School

AP (Sep. 15, 2014) The FDA is considering whether to ban devices used by the Judge Rotenberg Educational Center in Canton, Massachusetts, the only place in the country known to use electrical skin shocks as aversive conditioning for aggressive patients. (Sept. 15) Video provided by AP
Powered by NewsLook.com
Respiratory Virus Spreads To Northeast, Now In 21 States

Respiratory Virus Spreads To Northeast, Now In 21 States

Newsy (Sep. 14, 2014) The respiratory virus Enterovirus D68, which targets children, has spread from the Midwest to 21 states. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins